Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Mini Oral - Developmental therapeutics

537MO - First-in-human study of JNJ-64619178, a protein arginine methyltransferase 5 (PRMT5) inhibitor, in patients with advanced cancers

Date

18 Sep 2020

Session

Mini Oral - Developmental therapeutics

Presenters

Maria Vieito Villar

Citation

Annals of Oncology (2020) 31 (suppl_4): S462-S504. 10.1016/annonc/annonc271

Authors

M. Vieito Villar1, A. Spreafico2, V. Moreno Garcia3, I. Braña1, T. Hernandez3, A. Abdul Razak2, J.S. Wang4, N. Haddish-Berhane5, J. Mehta5, A. Johnson5, A. Maes6, J. Haslam5, P. Mistry7, A. Kalota5, L. Lenox5, J.R. Infante5, M.V. Lorenzi5, H. Xie5, J. Lauring5, M.R. Patel4

Author affiliations

  • 1 Medical Oncology Dept., Vall d'Hebron University Hospital, 8035 - Barcelona/ES
  • 2 Medical Oncology, Princess Margaret Cancer Centre, University of Toronto, Toronto/CA
  • 3 Clinical Research Phase 1 Trials Unit, START Madrid-FJD, University Hospital "Fundacion Jimenez Diaz", 28040 - Madrid/ES
  • 4 Medical Oncology, Florida Cancer Specialists/ Sarah Cannon Research Institute, Sarasota/US
  • 5 Oncology, Janssen Research & Development, Spring House/US
  • 6 Oncology, Janssen Pharmaceutica NV, Beerse/BE
  • 7 Biostatistics, Janssen Research & Development, High Wycombe/GB
More

Resources

Login to access the resources on OncologyPRO.

Abstract 537MO

Background

PRMT5 regulates proteins important for tumorigenesis via symmetric arginine dimethylation (SDMA). JNJ64619178 is an oral, potent and selective PRMT5 inhibitor that demonstrates efficacy in multiple tumor models. Here, we present a phase I study of JNJ64619178 in adults with advanced solid tumors and non-Hodgkin lymphoma (Part 1).

Methods

Dose escalation was supported by a modified continual reassessment method. Patients (pts) received JNJ64619178 either intermittently (14 days on/7 days off) or once daily (QD) on a 21-day cycle. Safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy were evaluated to identify the recommended phase II doses (RP2D).

Results

Fifty-four pts were enrolled as of 17 Mar 2020. The most common tumor types were adenoid cystic carcinoma (ACC; 20%), prostate cancer (15%), and uveal melanoma (13%). Median age was 59 (range 28-82), and median number of prior systemic therapies was 3 (range 0-11). Dosing ranged from 0.5 mg to 4 mg intermittently, and from 1 mg to 2 mg QD. Median treatment duration was 1.5 mo (range 0.4-22.4). The only dose-limiting toxicity observed was thrombocytopenia, at 3 and 4 mg intermittently and 2 mg QD. Fifty-one pts (91%) experienced treatment-related adverse events (TRAE), the most common being thrombocytopenia (52%), anemia (41%), nausea (39%), fatigue (32%), dysgeusia (30%), asthenia (24%), and diarrhea (20%). Grade 3/4 TRAEs in >1 pt were thrombocytopenia (20%), anemia (17%), and neutropenia (6%). Thirty pts (56%) had dose interruptions or reductions due to AE. JNJ64619178 plasma Cmax and AUC were linearly dose-proportional. Robust target engagement, as measured by plasma SDMA, was achieved even with intermittent dosing. A confirmed partial response (RECIST) was observed in ACC, and 7 pts (13%) with ACC, prostate cancer, salivary gland carcinomas, and other tumor types had stable disease >6 mo. Two provisional RP2Ds were selected: 1.5 mg intermittently and 1 mg QD.

Conclusions

JNJ64619178 demonstrated manageable toxicity and preliminary evidence of antitumor activity at selected dose levels. Intermittent dosing maintains target inhibition. Assessment of two provisional RP2Ds is ongoing.

Clinical trial identification

NCT03573310.

Editorial acknowledgement

Editorial assistance was provided by Ramji Narayanan of SIRO Clinpharm Pvt Ltd, funded by Janssen Global Services, LLC.

Legal entity responsible for the study

Janssen Research & Development, LLC.

Funding

Janssen Research & Development, LLC.

Disclosure

M. Vieito Villar: Advisory/Consultancy, Unpaid consultant: Debiopharma; Advisory/Consultancy, Unpaid consultant: Roche. A. Spreafico: Advisory/Consultancy: Merck; Advisory/Consultancy, Research grant/Funding (self): Bristol-Myers Squibb; Advisory/Consultancy, Research grant/Funding (self): Novartis ; Advisory/Consultancy: Oncorus; Research grant/Funding (self): Symphogen AstraZeneca/Medimmune; Research grant/Funding (self): Bayer; Research grant/Funding (self): Surface Oncology; Research grant/Funding (self): Northern Biologics; Research grant/Funding (self): Janssen; Research grant/Funding (self): Roche; Research grant/Funding (self): Array Biopharma. I. Braña: Advisory/Consultancy: MSD; Speaker Bureau/Expert testimony, Research grant/Funding (self): AstraZeneca; Speaker Bureau/Expert testimony, Research grant/Funding (self): Bristol-Myers Squibb; Research grant/Funding (self): Gliknik; Research grant/Funding (self): GlaxoSmithKline; Research grant/Funding (self): MSD; Research grant/Funding (self): Novartis; Research grant/Funding (self): Pfizer; Research grant/Funding (self): Shattuck Labs; Research grant/Funding (self): Roche; Speaker Bureau/Expert testimony: Merck Serono. J.S. Wang: Honoraria (self), Speaker Bureau/Expert testimony: AstraZeneca. N. Haddish-Berhane: Full/Part-time employment: Janssen. J. Mehta: Full/Part-time employment: Janssen. A. Johnson: Full/Part-time employment: Janssen. A. Maes: Full/Part-time employment: Janssen. J. Haslam: Full/Part-time employment: Janssen. P. Mistry: Full/Part-time employment: Janssen. A. Kalota: Full/Part-time employment: Janssen. L. Lenox: Full/Part-time employment: Janssen. J.R. Infante: Full/Part-time employment: Janssen. M.V. Lorenzi: Full/Part-time employment: Janssen. H. Xie: Full/Part-time employment: Janssen. J. Lauring: Full/Part-time employment: Janssen. M.R. Patel: Honoraria (self): Gilead; Honoraria (self): Exelixis; Honoraria (self): BMS; Honoraria (self): Genentech; Honoraria (self): Medivation. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings